News & Updates
Filter by Specialty:
CV safety of degarelix vs leuprolide: Results remain inconclusive
In men with prostate cancer and concomitant atherosclerotic cardiovascular disease (ASCVD), major adverse cardiovascular event (MACE) incidence did not differ between those who were treated with degarelix or leuprolide, according to findings of the PRONOUNCE trial.
CV safety of degarelix vs leuprolide: Results remain inconclusive
06 Oct 2021
Leuprolide acetate maintains QOL scores in prostate cancer patients despite worsening condition
Treatment with leuprolide acetate every 6 months does not elicit significant changes in health-related quality of life (HRQOL) among prostate cancer (PC) patients despite substantial deterioration of body and role functions, a recent study has found.
Leuprolide acetate maintains QOL scores in prostate cancer patients despite worsening condition
05 Oct 2021
YouTube a good way to educate patients about male infertility
YouTube has increasingly become an avenue for delivering information about male infertility, though crucial knowledge gaps still exist, a recent study has found.
YouTube a good way to educate patients about male infertility
03 Oct 2021
Low-intensity shockwave with PDE-5i safe, effective for erectile dysfunction
The combination of low-intensity shockwave therapy (Li-ESWT) with phosphodiesterase 5 inhibitor (PDE-5i) medication safely improves erectile function in vasculogenic erectile dysfunction (ED) patients who had failed first-line oral therapy, a recent study has found.
